Navigation Links
Northwest Biotherapeutics to Present at Next Generation Vaccine Conference
Date:7/17/2008

is news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in the Phase II trial of DCVax(R)-Brain and complete the trial on a timely basis, risks related to meeting the clinical endpoints in the planned Phase II clinical trial of DCVax(R)-Brain, risks related to manufacturing, risks related to the Company's ability to initiate, and enroll patients in, the planned Phase III trial of DCVax(R)-Prostate and complete the trial on a timely basis, the uncertainty of the clinical trials process and whether DCVax(R)-Prostate or DCVax(R)-Brain will demonstrate safety and efficacy, and the timely performance of third parties. Additional information on these and other factors, which could affect the Company's results, is included in its Securities and Exchange Commission filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.


'/>"/>
SOURCE Northwest Biotherapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Northwestern chemist investigates lost reds in Homer painting
2. Nikon Instruments Opens New Imaging Center at Northwestern University
3. Northwest Secures US$4.0 Million in Debt Financing
4. Cell Therapeutics, Inc. (CTI) Invest Northwest Presentation to be Webcast
5. Cell Therapeutics, Inc. (CTI) to Present at 7th Annual WBBA Invest Northwest Conference
6. Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics
7. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
8. CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership
9. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
10. Protalix BioTherapeutics Signs Lease Agreement for Expansion of its Manufacturing and Research Facility in Carmiel, Israel
11. Protalix BioTherapeutics Sets Record Date for Annual Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Bryan-College Station, Texas (PRWEB) September 18, 2014 ... University System Chancellor John Sharp, Texas A&M Health ... from the U.S. Department of Health and Human ... GSK today dedicated a national pandemic influenza vaccine ... will serve as an anchor for the Texas ...
(Date:9/18/2014)... 18, 2014 Research and Markets ... Albumin Industry Report 2014" report to their offering. ... 2014 is a professional and in-depth study on the ... The report provides a basic overview of the ... The human albumin market analysis is provided for the ...
(Date:9/18/2014)... , Sept. 18, 2014  MEI Pharma, Inc. (Nasdaq: ... clinical development of novel therapies for cancer, announced today that ... Officer, will present at BioCentury,s NewsMakers in the Biotech ... a.m. Eastern time from the Millennium Broadway Hotel & Conference ... webcast of the presentation can be accessed at www.meipharma.com ...
(Date:9/18/2014)... 18, 2014   Sigma-Aldrich Corporation (Nasdaq: ... entered into a new gene editing partnership with ... Core. Under the partnership, Sigma-Aldrich will provide the ... consultation, and dedicated gene editing bioinformaticians. ... research at the U-M Medical School. One initiative ...
Breaking Biology Technology:Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 4
... 2011 Insmed Incorporated (Nasdaq: INSMD), a biopharmaceutical company, ... (IND) to conduct a pivotal Phase 3 clinical trial ... nontuberculous mycobacteria (NTM) lung infections has been cleared by ... In 2010, Insmed initially submitted a regulatory filing ...
... 2011 Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: ... pivotal trial of pixantrone for the treatment of relapsed/refractory ... now open to patient enrollment. The trial, referred to ... a combination of pixantrone plus rituximab to a combination ...
... Driving value for customers is critical to organizational success across ... customer and an organization, there has to be an integrated ... succeed in the marketplace. Chris Bogan, CEO ... in this month,s special issue of PharmaVoice that the state ...
Cached Biology Technology:Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication 2Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication 3Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication 4Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication 5Cell Therapeutics Initiates Pixantrone PIX-R Pivotal Trial for Treatment of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma 2Cell Therapeutics Initiates Pixantrone PIX-R Pivotal Trial for Treatment of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma 3Cell Therapeutics Initiates Pixantrone PIX-R Pivotal Trial for Treatment of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma 4Best Practices, LLC Showcases Its Expertise in Customer Relationship Management 2
(Date:9/18/2014)... that can operate inside the bore of an MRI ... biomedical research partnership program at Brigham and Women,s Hospital ... robot, in conjunction with real-time MRI images, can make ... less discomforting for the patient. The novel system also ... greater precision. , Developed by a team of robotics ...
(Date:9/18/2014)... Americans to undertake jaunts into the countryside each year could ... a century, according to new research. , Climate change could ... States as summer temperatures linger later into the year, Princeton ... Biogeography . For instance, the paper birch a popular ... could change color one to three weeks later by ...
(Date:9/18/2014)... -- Arizona turned its newborn screening program into a model ... earning it the first-ever Newborn Screening Quality Award from the ... Will Humble, M.P.H., Arizona,s Department of Health Services director, with ... established a policy of full transparency for the length of ... to the lab for analysis, and set a target of ...
Breaking Biology News(10 mins):Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Fall foliage season may be later, but longer on warmer Earth 2Fall foliage season may be later, but longer on warmer Earth 3Fall foliage season may be later, but longer on warmer Earth 4March of Dimes honors Arizona with first-ever newborn screening award 2March of Dimes honors Arizona with first-ever newborn screening award 3
... has declined steadily in the last three decades. Although ... groups have shown some improvement, according to a recent ... the American Association for Cancer Research. "Our ... treatment, have resulted in profound gains, but these gains ...
... Barbara, Calif.) Scientists at UC Santa Barbara have found ... findings are published online in this week,s issue of the ... species differences in how they use the environment are key ... around us, but the importance of such niches have never ...
... the human brain reshapes itself to store this newfound knowledge. ... does that capacity to adapt reflect our risk for Alzheimer,s ... lives? Dr. Yaniv Assaf of Tel Aviv University,s Department ... effect of memory on brain structure. "With a specific MRI ...
Cached Biology News:Cancer mortality rates experience steady decline 2Scientists demonstrate importance of niche differences in biodiversity 2A window into the brain 2
... cells (HSC) are well-characterized tissue-specific stem cells ... responsible for the life-long maintenance of the ... reside in adult bone marrow where hematopoiesis ... be found in cord blood, fetal liver, ...
Human DEP-1/CD148 Fluorescein MAb (Clone 143-41) Protein Family: Granulocyte Markers, Monocyte Markers, Phosphatases & Regulators, Other Dendritic Cell Molecules...
MOUSE ANTI PORCINE SLA 1:FITC Immunogen: Porcine peripheral blood mononuclear cells....
NNT-1/BSF-3 (N-14)...
Biology Products: